The aim of the work is to present a simple LC-MS/MS approach for a sensitive, specific, and quantitative determination of Tucatinib in human K2EDTA plasma. Tucatinib is used in the treatment of metastatic HER2-positive breast cancer. Linearity and a high r2 value (>0.99) characterize the calibration curve, which spans 1–2,000 ng/ml. The quality control levels were executed with plasma blank to get 1, 3, 1,000, and 1,500 ng/ml for the lower limit of quantification, LQC,low quality control, MQC, and high quality control, respectively. The relative errors for the intra- and inter-batches were from 3.49% to 4.75% and 2.82% to 4.14%, correspondingly, with coefficient variation varying from −3.02% to 5.21% and 2.82% to 5.12%. During the retention period of Tucatinib and internal standard, there was no discernible interference from the endogenous peak. No matrix impact was seen in the test samples and was stable throughout the conditions exposed; moreover, recoveries were accurate across the whole calibration curve range. As per the USFDA bioanalytical technique validation guideline, the LC-MS/MS method was validated in terms of accuracy, linearity, precision, specificity, stability, dilution integrity, extraction recoveries, selectivity, and matrix effect. In conclusion, a new approach to evaluating Tucatinib in human K2EDTA plasma has been approved for use in clinical, bioavailability, and bioequivalence investigations, and it may be used to quantify Tucatinib.
Pawar SD, Kayande DD, Pawar K, Farooqui M, Shankarwar A, Deshpande A, Shankarwar S. Development of a validated LC–ESI-MS/MS method for the quantification of tucatinib in plasma samples. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.213916
1. Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020 Apr;19(4):976–87. doi: https://doi.org/10.1158/1535-7163.MCT-19-0873
2. Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018 Sep 1;4(9):1214–20. doi: https://doi.org/10.1001/jamaoncol.2018.1812
3. Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 Jul;19(7):880–8. doi: https://doi.org/10.1016/S1470-2045(18)30256-0
4. Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC). Clin Cancer Res. 2017 Jul 15;23(14):3529–36. doi: https://doi.org/10.1158/1078-0432.CCR-16-1496
5. Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018 Jun;67:71–7. doi: https://doi.org/10.1016/j.ctrv.2018.05.004
6. Paul MK, Mukhopadhyay AK. Tyrosine kinase -role and significance in cancer. Int J Med Sci. 2004;1(2):101–15. doi: https://doi.org/10.7150/ijms.1.101
7. Topletz-Erickson AR, Lee AJ, Mayor JG, Sun H, Abdulrasool LI, Rustia EL, et al. The pharmacokinetics and safety of tucatinib in volunteers with hepatic impairment. Clin Pharmacokinet. 2022;61(12):1761–70. doi: https://doi.org/10.1007/s40262-022-01183-6
8. Reehana SK, Sujana K. LC-MS/MS characterization of forced degradation products of tucatinib, a novel tyrosine kinase inhibitor: development and validation of RP-HPLC method. Int J Appl Pharm. 2022;14(1):58–66. doi: http://doi.org/10.22159/ijap.2022v14i1.43252
9. Henion J, Brewer E, Rule G. Sample preparation for LC/MS/ MS: knowing the basic requirements and the big picture of an LC/ MS system can ensure success in most instances. Anal Chem. 1998;70:650A–6A. doi: http://doi.org/10.1021/ac981991q
10. FDA Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) May 2001. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf?utm_source=chatgpt.com
11. ICH. Q2B. Harmonized tripartite guideline, validation of analytical procedure: methodology, IFPMA. Proceedings of the International Conference on Harmonization; International Conference on Harmonization; Geneva, Switzerland: ICH; 1996. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf?utm_source=chatgpt.com
12. Tandrima M, Shiva Kumar G. Development and validation of LC–MS/MS method for alpelisib quantification in human plasma: application to pharmacokinetics in healthy rabbits. J Appl Pharm Sci. 2023;13(3):89–96. doi: https://doi.org/10.7324/JAPS.2023.75269
13. Khadernaick AB, Gubbiyappa KS. Application of validated LCMS/ MS method development to quantify pexidartinib in biological media: in-vivo bioavailability studies in healthy rabbits. J Appl Pharm Sci. 2021;11(6):78–86. doi: http://doi.org/10.7324/JAPS.2021.110609
14. Murphy AT, Kasper SC, Gillespie TA, DeLong AF. Determination of xanomeline and active metabolite, N-desmethylxanomeline, in human plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Appl. 1995;668:273–80. doi: http://doi.org/10.1016/0378-4347(95)00080-3
15. Richard Hoetelmans MW, Van Essenberg M, Pieter Meenhorst L, Jan Mulder W, Jos Beijnen H. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 1997;698:235–41. doi: http://doi.org/10.1016/S0378-4347(97)00268-5
16. Ravi Y, RBhikshapathi D, Cheruku S, Rajkamal B. Development of fast and simple LC-ESI-MS/MS technique for the quantification of regorafenib; application to pharmacokinetics in healthy rabbits. Curr Pharm Anal. 2021;17(4):554–63. doi: http://doi.org/10.2174/1573412916666191111144707
17. Lolla S, Gubbiyappa KS, Cheruku S, Bhikshapathi DVRN. Validation of an LC-MS/MS method for quantitation of fostemsavir in plasma. J Pharmacol Toxicol Methods. 2023 Mar–Apr;120:107254. doi: https://doi.org/10.1016/j.vascn.2023.107254
18. Nagalakshmi V, Srinivas Rao G, Gayathri Devi N, Mohan S. RP-HPLC method for simultaneous estimation of vildagliptin and metformin in bulk and pharmaceutical formulations. IJCRR. 2021;13(7):112–7. doi: http://doi.org/10.31782/IJCRR.2021.13710
19. Kumar PP, Murthy TE, Basaveswara Rao MV. Development, validation of liquid chromatography–tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. J Adv Pharm Technol Res. 2015;6:118–24. doi: http://doi.org/10.4103/2231-4040.157982
20. Kalluru H, Vinodhini C, Srinivas KS, Rajan MS, Chitra K, Mangathayaru K. Validated RP-HPLC method for quantification of paclitaxel in human plasma—eliminates negative influence of cremophor EI. IJCRR. 2018;10(13):5–10. doi: http://doi.org/10.31782/IJCRR.2018.10132
21. Saraner N, Karagoz A, Guney B, Saglam O. Determination of dasatinib in human plasma by using liquid chromatography-tandem mass spectrometry. Int J Analyt Bioanalyt Methods. 2019;1:2. doi: https://doi.org/10.1016/j.jchromb.2016.03.024
22. Sai Uday Kiran G, Sandhya P, Shankar CH, Bhikshapathi DVRN, Mamatha P. An LC–MS/MS quantification method development and validation for the dabrafenib in biological matrices. J Appl Pharm Sci. 2023;13(1):180–6. doi: https://doi.org/10.7324/JAPS.2023.130117
Year
Month